1 |
IFNG
| 10件: Proteasome Proteasome, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis | D04242
D04242
|
Fontolizumab
| 1件: 46 46 |
2 |
IFNG
| 10件: Proteasome Proteasome, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis | D11120
D11120
|
Emapalumab
| 2件: 49 49, 107 |
3 |
PSMB5
(Full name: proteasome 20S subunit beta 5) | 8件: Proteasome Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases | D03150
D03150
|
Bortezomib
| 16件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 |
4 |
PSMB5
(Full name: proteasome 20S subunit beta 5) | 8件: Proteasome Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases | D08880
D08880
|
Carfilzomib
| 1件: 28 28 |
5 |
PSMB5
(Full name: proteasome 20S subunit beta 5) | 8件: Proteasome Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases | D10130
D10130
|
Ixazomib
| 5件: 13 13, 16, 28, 51, 61 |